AnaptysBio (NASDAQ:ANAB) Price Target Lowered to $66.00 at JPMorgan Chase & Co.

AnaptysBio (NASDAQ:ANAB) had its target price decreased by JPMorgan Chase & Co. from $75.00 to $66.00 in a research report released on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

A number of other brokerages have also recently weighed in on ANAB. Wedbush reissued an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research note on Wednesday, November 6th. Guggenheim raised their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Truist Financial boosted their price target on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. UBS Group lifted their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, HC Wainwright decreased their price target on AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

AnaptysBio Stock Performance

AnaptysBio stock opened at $21.50 on Tuesday. AnaptysBio has a fifty-two week low of $13.36 and a fifty-two week high of $41.31. The firm has a market capitalization of $654.25 million, a price-to-earnings ratio of -3.69 and a beta of -0.24. The stock’s fifty day moving average is $32.35 and its two-hundred day moving average is $30.02.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. As a group, sell-side analysts forecast that AnaptysBio will post -6.18 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In related news, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the completion of the sale, the insider now owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the transaction, the insider now owns 7,020 shares in the company, valued at approximately $279,536.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock worth $892,936 in the last three months. 33.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors have recently made changes to their positions in the business. Values First Advisors Inc. acquired a new stake in AnaptysBio in the third quarter valued at $49,000. nVerses Capital LLC increased its stake in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in AnaptysBio during the first quarter worth about $38,000. Headlands Technologies LLC lifted its holdings in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 2,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 2,600 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.